
    
      Healthy subjects:

      The total duration of study per subject is up to 4.5 weeks with 2 to 21 days screening
      period, 1 day for treatment, and 7 days (+/- 1 day) follow-up after IMP administration.

      T1DM patients:

      The total duration of study per patient is up to 5.5 weeks with 3 to 28 days screening
      period, 1 day for treatment, and 7 days (+/- 1 day) follow-up after IMP administration.

      One or more interim analyses may be performed to support decisions for the next steps of the
      study.
    
  